The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Survey data published in JAMA Neurology indicate that approximately half of US adults perceive themselves to be at least somewhat likely to develop dementia.
The global intensity of the tau-positron emission tomography (PET) signal predicts the rate of subsequent atrophy in patients at early symptomatic Alzheimer disease (AD) stages.
In women, midlife obesity is associated with increased risk for dementia later in life, while no clear associations are apparent for low body mass index (BMI), low caloric intake, or inactivity at baseline.
The FDA has accepted for review the resubmitted New Drug Application (NDA) for apomorphine sublingual film (APL-130277; Sunovion) for the treatment of OFF episodes in patients with Parkinson disease (PD).
The FDA has approved the supplemental New Drug Application for riluzole oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of ALS.
Medical history, cognitive and physical examination, laboratory testing, and brain imaging can help identify causes of dementia, and several pharmacologic and nonpharmacologic approaches can help manage the disease.
